Index Options
CME Group
Nasdaq
Cboe
TradingView
Wall Street JournalNews
AKRO
44.82
+1.52%
0.67
Weekly Report: what happened at AKRO last week (0310-0314)?
Weekly Report · 16h ago
Weekly Report: what happened at AKRO last week (0303-0307)?
Weekly Report · 03/10 09:05
Evercore ISI Reaffirms Their Buy Rating on Akero Therapeutics (AKRO)
TipRanks · 03/07 07:48
Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)
TipRanks · 03/03 12:50
Akero Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/03 12:28
Akero Therapeutics Price Target Raised to $75.00/Share From $72.00 by HC Wainwright & Co.
Dow Jones · 03/03 12:28
Akero Therapeutics: Strong Financials and Promising Clinical Progress Justify Buy Rating
TipRanks · 03/03 11:45
Promising Developments and Strong Financial Position Support Buy Rating for Akero Therapeutics
TipRanks · 03/03 11:26
Akero Therapeutics price target raised to $75 from $72 at H.C. Wainwright
TipRanks · 03/03 11:16
Weekly Report: what happened at AKRO last week (0224-0228)?
Weekly Report · 03/03 09:05
U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund
Reuters · 03/03 07:43
Akero Therapeutics price target lowered to $90 from $96 at Morgan Stanley
TipRanks · 03/02 16:35
Akero Therapeutics: Buy Rating Backed by Groundbreaking Clinical Results and Strong Financial Position
TipRanks · 03/02 13:55
Akero Therapeutics Reports Promising Clinical Trial Results
TipRanks · 03/01 04:17
Based on the provided financial report articles, the title of the article is:
"FORM 10-K"
This is an annual report filed by Akero Therapeutics, Inc. with the Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2024.
Press release · 03/01 00:33
Akero Therapeutics: Strong Financial Health and Promising Clinical Trial Results Drive Buy Rating
TipRanks · 02/28 21:15
Biotech Alert: Searches spiking for these stocks today
TipRanks · 02/28 16:20
AKERO THERAPEUTICS INC - Q4 SHR LOSS $0.99
Reuters · 02/28 13:36
Akero Therapeutics Inc. Q4 Loss Beats Estimates
NASDAQ · 02/28 13:12
Akero Therapeutics GAAP EPS of -$0.99 beats by $0.17
Seeking Alpha · 02/28 12:15
More
Webull provides a variety of real-time AKRO stock news. You can receive the latest news about Akero Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About AKRO
MoreAkero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.